Table of Contents

List of Figures....................xii

List of Tables....................xviii

Abbreviations....................xix

Preface....................xxii

1. **Chapter 1: Introduction**....................1

9.1 Background....................1

9.2 Anacardic Acid activity against Biofilms....................3

9.3 Anacardic Acid activity against Photoaging....................8

2. **Chapter 2: Literature review**....................11

2.1. Anacardic Acid....................11

2.1.1 Pharmacological Activities of Anacardic Acid....................12

2.1.2 Physicochemical properties of Anacardic Acid....................14

2.1.3 Recent studies on Anacardic Acid....................14

2.2. Microbial infection....................16

2.3. Microbial resistance to antibiotics....................17

2.4. Mechanisms of antibiotic resistance....................17

2.5. Biofilm and biofilm mediated antimicrobial resistance....................18

2.5.1 Stages in biofilm formation....................19

2.5.2 Components of biofilm....................21

2.5.3 Complications associated with biofilm mediated infections....................23

2.5.4 Biofilm mediated resistance to antibiotics....................23

2.5.5 Diseases associated with biofilm formation....................25

2.5.6 Prevention and therapy of biofilm related complications....................26

2.6. UV-B mediated skin photoaging....................36

2.6.1 Aging....................36

2.7. UV radiation and skin photoaging....................38

Scanned with CamScanner

2.8. UV-B radiation and biochemical changes in skin 39
2.9. Treatment approaches 41
2.9.1 Preventive approach 41
2.9.2 Topical retinoids 42
2.9.3 Alpha hydroxy acids 43
2.9.4 Antioxidants 43
2.10. Role of Anacardic Acid in management of skin photoaging 45
2.11. Cyclodextrin nanosponge for skin delivery 46
3. Chapter 3: Objectives 49
4. Chapter 4: Plan of study 50
5. Chapter 5: Extraction and isolation of Anacardic Acid 53
5.1 Extraction of Cashew Nut Shell Liquid (CNSL), and group isolation of Anacardic Acid 53
5.1.1 Extraction of CNSL 53
5.1.2 Isolation of Anacardic Acid from CNSL 53
5.1.3 Isolation of C15:3 and C15:0 among the Anacardic Acid subtypes 54
5.2 HPLC analysis 54
5.3 Identification of the compounds using FT-IR and ^{1}H NMR 55
4.4.1 FT-IR 55
5.3.1 ^{1}H NMR 55
5.4 Results and Discussion 55
5.4.1 HPLC analysis 56
5.4.2 FT-IR 57
5.4.3 ^{1}H NMR 57
6. Chapter 6: Preparation and evaluation of Ana$_{C15:3}$/HP-β-CD inclusion complex 59
6.1 Materials 59
6.2 Methods 59

Scanned with CamScanner

6.2.1 Analytical method 59

6.2.2 Preparation of $Ana_{C15:3}$/HP-β-CD inclusion complex 60

6.2.3 Evaluation of $Ana_{C15:3}$/HP-β-CD inclusion complex 60

6.2.4 Antimicrobial activity 63

6.3 Results and Discussion 65

6.3.1 Analytical method 65

6.3.2 UV–Visible spectroscopy 66

6.3.3 Preparation of Anacardic Acid/HP-β-CD inclusion complex 67

6.3.4 Phase solubility study 68

6.3.5 Fourier transform infrared spectroscopy (FT-IR) 70

6.3.6 X-ray diffraction (XRD) study 72

6.3.7 Differential scanning calorimetry (DSC) 73

6.3.8 Scanning Electron Microscopy 74

6.3.9 ^{1}H NMR (Proton) Spectroscopy 75

6.3.10 Antimicrobial Activity 77

7. Chapter 7: Development of Chitosan and DNase coated solid lipid nanoparticles encapsulating Anacardic Acid ($Ana_{C15:3}$) 82

7.1 Materials 82

7.2 Methods 82

7.2.1 Preparation of Anacardic Acid loaded solid lipid nanoparticles 82

7.2.2 Chitosan and DNase coated SLNs 83

7.2.3 Characterization of Ana-loaded SLNs 83

7.2.4 Antimicrobial study 86

7.2.5 Statistical analysis 99

7.3 Results and Discussion 89

7.3.1 Characterization of $Ana_{C15:3}$-SLNs 89

7.3.2 Antimicrobial study 96

Scanned with CamScanner

8. **Chapter 8: Preparation and evaluation Ana$_{C15:0}$ nanosponge based gel** 103

8.1 Materials 103

8.2 Methods 103

8.2.1 Analytical method 103

8.2.2 Synthesis of β-Cyclodextrin Nanosponge 104

8.2.3 Preparation of Ana$_{C15:0}$ loaded Nanosponge complex 104

8.2.4 Optimization of Ana$_{C15:0}$-NS formulation using 3-level factorial design 105

8.2.5 Evaluation of Ana$_{C15:0}$-Nanosponge 105

8.2.6 Preparation of Ana$_{C15:0}$-NS enriched topical gel 107

8.2.7 Evaluation of Ana$_{C15:0}$-NS topical gel 108

8.2.8 Animal Study 109

8.3 Results and Discussion 111

8.3.1 Analytical method 112

8.3.2 Formulation optimization 113

8.3.3 Solubility study 116

8.3.4 Fourier transform infrared spectroscopy 117

8.3.5 X-ray diffraction (XRD) study 118

8.3.6 Morphology evaluation of Ana$_{C15:0}$ encapsulated nanosponge 120

8.3.7 *In-vitro* release study 120

8.3.8 Evaluation of Ana$_{C15:0}$-NS topical gel 121

8.3.9 Physical evaluation of skin photoaging 123

8.3.10 Histopathology study 124

8.3.11 Estimation of biochemical parameters 125

9. **Chapter 9: Summary & conclusion** **129**

9.1 Summary 129

9.2 Conclusion 133

11. References **135**

Scanned with CamScanner

List of Figures

Figure No	Description	Page No
Figure 1.1:	Chemical structure of Anacardic Acid and its subtypes	1
Figure 1.2:	Photograph demonstrating various stages of Staphylococcus aureus biofilm formation and proposed formulation approaches to combat biofilm.	7
Figure 1.3:	Photograph illustrating skin photoaging pathway, Anacardic Acid ($_{C15:0}$) activity and formulation approach to improve photoaging therapy.	10
Figure 2.1:	Overview of different components mixture of solvent extracted CNSL	12
Figure 2.2:	Solar UV radiations and its penetration in skin layers	39
Figure 2.3:	Biochemical routes of UV-B mediated skin photoaging and course of Anacardic Acid action	46
Figure 5.1:	Representative HPLC profiles of Anacardic Acid (a), $Ana_{C15:3}$ (b), and $Ana_{C15:0}$ (c).	56
Figure 5.2:	Comparative FT-IR spectra of $Ana_{C15:3}$ (a) and $Ana_{C15:0}$ (b).	57
Figure 5.3:	1H NMR spectra of $Ana_{C15:3}$ (a) and $Ana_{C15:0}$ (b).	58
Figure 6.1:	Calibration curve of $Ana_{C15:3}$ in ethanol (A) and phosphate buffer pH 6.8 (B) for UV spectrophotometry.	66
Figure 6.2:	UV absorption spectra $Ana_{C15:3}$ in phosphate buffer pH 6.8 at different HP-β-CD concentrations: (1) 0.00 mM, (2) 10.00 mM, (3) 20.00 mM and (4) 25.00 mM	67
Figure 6.3:	Phase solubility diagram of $Ana_{C15:3}$ as a function of HP-β-CD concentrations in phosphate buffer pH 6.8 at different temperatures (A) 25°C, (B) 35°C and (C) 45°C.	69
Figure 6.4:	The FT-IR spectra of HP β-CD (A), $Ana_{C15:3}$ (B), and inclusion complex (C).	71
Figure 6.5:	X-ray diffraction patterns of HP-β-CD (A), $Ana_{C15:3}$ (B),	72

Scanned with CamScanner

and inclusion complex (C).

Figure 6.6: DSC thermograms of HP-β-CD (A), $Ana_{C15:3}$ (B), and the inclusion complex (C). 74

Figure 6.7: Scanning electron microscopy image of HP-β-CD (A) and Inclusion complex (B). 75

Figure 6.8: Comparative 1H NMR spectrum of HP-β-CD (A), $Ana_{C15:3}$ (B), and inclusion complex (C). 76

Figure 6.9: Disruption effect of free $Ana_{C15:3}$ and $Ana_{C15:3}$-IC on mature biofilm grown in 96 well plates. The graph depicts the percentage biofilm residue in response to different concentration of $Ana_{C15:3}$ and $Ana_{C15:3}$-IC. The study demonstrates a reduction of 48 h grown S. aureus biofilm on a single dose (Figure 6.9-A) and repeated dose for three recurrent days (Figure 6.9-B) of different $Ana_{C15:3}$ and $Ana_{C15:3}$-IC concentrations. The data represent a mean ± standard deviation (n=3). ap < 0.005 as compared to $Ana_{C15:3}$ (Two way ANOVA followed by Bonferroni test). ns indicates the results are not significant as compared between the two groups. The viable count for the control experiment without $Ana_{C15:3}$ were 2.39×109 ± 1.19×108 CFU/mL. 79

Figure 6.10: CLSM image of S. aureus biofilm formed on the coverslip surface with media supplementation. The images demonstrate dense biofilms formed without treatment (A) or with $Ana_{C15:3}$ (B) and $Ana_{C15:3}$-IC (C) treatment. The live cells are indicated by colored fluorescence while the dead cells appear as red colored cells. The control group demonstrates more green colored cells indicating live bacterial cells while the $Ana_{C15:3}$-IC treated group exhibited maximum red colored cells indicating dead cells. 80

Figure 7.1: TEM image of $Ana_{C15:3}$-SLNs-CH-DNase 91

Scanned with CamScanner

Figure 7.2: FT-IR spectra of $Ana_{C15:3}$ (A), $Ana_{C15:3}$-SLNs (B), and Blank SLNs (SLNs without $Ana_{C15:3}$ (C) and $Ana_{C15:3}$-SLNs-CH-DNase (D) **92**

Figure 7.3: XRD plots of $Ana_{C15:3}$ (A), Blank SLNs (SLNs without $Ana_{C15:3}$) (B) and $Ana_{C15:3}$-SLNs (C) and $Ana_{C15:3}$-SLNs-CH-DNase (D) **93**

Figure 7.4: Plot indicates the cumulative amount of $Ana_{C15:3}$ release on Y axis with respect to time on X axis from the $Ana_{C15:3}$ and $Ana_{C15:3}$-SLNs-CH-DNase in phosphate buffer (PBS, pH 6.8) as release media containing 0.1% SLS to maintain the sink conditions. **94**

Figure 7.5: Bar diagrams representing the results of the in vitro toxicity study (MTT assay). Data are represented as mean±SD (n=3). No significant differences were observed among the different treatments (One-way ANOVA followed by Newman keul's post hoc test). **95**

Figure 7.6: Inhibition of S. aureus biofilm formation following the different treatments. Graph represents the percentage biofilm residue following the treatment with different concentration of $Ana_{C15:3}$. The results are presented as the mean ± standard deviation of three replicates from three independent experiments. Two-way ANOVA was performed (where a represents $p < 0.05$ in comparison with biofilms not receiving any treatment i.e. concentration of $Ana_{C15:3}$= 0 μg/mL). The viable cell count in the control experiments without Ana was 2.41×109±1.09×108 CFU/mL. **97**

Figure 7.7: Disassembling of mature biofilm following the treatment with a single dose (A) and repeated dose (B). The data represents the percentage of biofilm residue that remained following the treatments. The values are expressed as mean **100**

Scanned with CamScanner

± standard deviation of three replicates from three independent experiments. Two-way ANOVA was performed (where arepresents $p < 0.05$ as compared with $Ana_{C15:3}$-SLNs-CH-DNase). The viable cell count in the control experiments without $Ana_{C15:3}$ was 2.91×109±1.13×108 CFU/mL.

Figure 7.8: CLSM image showing S. aureus biofilm formation without any treatment (A) and following the treatment with $Ana_{C15:3}$ (B), $Ana_{C15:3}$-SLNs (C), $Ana_{C15:3}$-SLNs-CH (D), $Ana_{C15:3}$+DNase (E), and $Ana_{C15:3}$-SLNs-CH-DNase treatment. The cells of the biofilm were stained using the Live/Dead BacklightTM bacterial viability kit. CLSM images demonstrate the staining pattern of live cells (SYTO-9, green) and dead cells (propidium iodide, red). 102

Figure 8.1: Calibration curve of $Ana_{C15:0}$ in ethanol (A), and phosphate buffer pH 6.8 (B) by using UV spectrophotometry. The graph indicates the absorbance at Y axis in response to the different concentrations on X axis. 112

Figure 8.2: 3D plots indicating the effect of different formulation variables on PS (A) and EE% (B). 115

Figure 8.3: Comparative solubility profiles of $Ana_{C15:0}$ and different ratios of $Ana_{C15:0}$:NS. All experiments were performed in triplicate and data represented as mean±S.D (n=3). arepresents significant difference as compared to $Ana_{C15:0}$. a,brepresents significant difference compared to $Ana_{C15:0}$-NS (1:2). $P<0.005$, one-way ANOVA followed by Newman-Keuls multiple-comparison test. 117

Figure 8.4: FT-IR spectra of HP-β-CD (A), $Ana_{C15:0}$ (B), and $Ana_{C15:0}$-Nanosponge (C) 118

Figure 8.5: XRD spectra of HP-β-CD (A), $Ana_{C15:0}$ (B) and $Ana_{C15:0}$-Nanosponge (C). 119

Scanned with CamScanner

Figure 8.6:	Photograph showing a TEM image of $Ana_{C15:0}$-NS	**120**
Figure 8.7:	In-vitro drug release profiles of $Ana_{C15:0}$ and $Ana_{C15:0}$-NS. Graph represents the cumulative amount of $Ana_{C15:0}$ with respect to time	**121**
Figure 8.8:	(A) Cumulative amount of drug permeated through skin with respect to time from $Ana_{C15:0}$-gel and $Ana_{C15:0}$-NS-gel. (B) Percentage drug retained in different compartments from $Ana_{C15:0}$-gel and $Ana_{C15:0}$-NS-gel. All data are presented as mean±SD (n=3) *represents significant difference compared to $Ana_{C15:0}$-gel, P<0.001 two-way ANOVA followed by Bonferroni posttest.	**123**
Figure 8.9:	Photographs indicating the effect of UV-B radiation on the animals in different treatment groups. There was no visible lesion or redness in the control group (I), severe photoaging could be observed in the UV-B irradiated group (II), whereas the severity decreases on treatment with $Ana_{C15:0}$-gel (IV) and $Ana_{C15:0}$-NS gel (v)	**124**
Figure 8.10:	Histological examination of the H&E stained dorsal skin samples taken from different groups; control (a), UVB-irradiated (b), Blank gel treated (c), 0.1% $Ana_{C15:0}$-gel treated, and 0.1% $Ana_{C15:0}$-NS gel treated group.	**125**
Figure 8.11:	Effect of different treatment groups on ROS production. All data are presented as mean±SD (n=3) arepresents significant difference as compared to UV-B irradiated group b represents significant difference compared to control crepresents significant difference compared to Blank gel drepresents significant difference compared to $Ana_{C15:0}$-gel. P<0.005 one-way ANOVA followed by Newman-Keuls multiple-comparison test.	**126**
Figure 8.12:	Effect of different treatment groups on the expression of MMP-1 & HAT p300 enzymes (A), relative level of HAT	**128**

Scanned with CamScanner

P300 among various groups (B), and relative MMP-1 level in different groups under study. All data are presented as mean±SD (n=6) a represents significant difference as compared to UV-B irradiated group brepresents significant difference as compared to control, crepresents significant difference as compared to Blank gel drepresents significant difference as compared to $Ana_{C15:0}$-gel $P<0.005$ one-way ANOVA followed by Newman-Keuls multiple-comparison test.

Scanned with CamScanner

List of Tables

Table No:	Description	Page No:
Table 2.1:	Physicochemical properties of Anacardic Acid	13
Table 2.2:	Summary of various pharmacological activities of Anacardic Acid.	14
Table 6.1:	List of chemicals used in the preparation of inclusion complex	59
Table 6.2:	Various parameters for calculation of stability constant	70
Table 6.3:	Variation of the ^{1}H NMR chemical shifts (δ /ppm) of $Ana_{C15:3}$ and HP-β-CD in inclusion complex formation.	77
Table 6.4:	Biofilm parameters of S. aureus biofilms without treatment (control), $Ana_{C15:3}$, and $Ana_{C15:3}$-IC treatment.	81
Table 7.1:	List of chemicals used in the study	82
Table 7.2:	Data representing particle size, PDI, and zeta potential of different formulations.	90
Table 7.3:	Illustration of variation in particle size and encapsulation efficiency following the storage of SLNs at different temperature conditions.	95
Table 7.4:	Data displaying biomass and thickness of biofilm upon treatment with different formulations.	101
Table 8.1:	List of materials used in the study	103
Table 8.2:	Experimental design demonstrating PS and EE% of the different formulation batches	113
Table 8.3:	Identified independent variables with their levels used in 3-level factorial experimental design and the optimized levels of the variables	115
Table 8.4:	Predicted values of PS and EE% based on the optimized level and the experimental response obtained	116
Table 8.5:	Changes in mechanical properties of hydrogel upon the incorporation of $Ana_{C15:0}$-NS	122

Scanned with CamScanner

List of Abbreviations and Symbols

Anacardic Acid	:	Ana
Anacardic Acid C15:0	:	$Ana_{C15:0}$
Anacardic Acid C15:3	:	$Ana_{C15:3}$
Analysis of Variance	:	ANOVA
Carbonyldiimidazole	:	CDI
Chitosan	:	CH
Centimeter	:	cm
Colony Forming Unit	:	CFU
Confocal Laser Scanning Microscopy	:	CLSM
Cyclodextrin	:	CD
β-Cyclodextrin	:	β-CD
Deoxyribonuclease-I	:	DNase
Differential Scanning Calorimetry	:	DSC
Dimethyl Formamide	:	DMF
Entrapment Efficiency	:	EE
Extracellular DNA	:	e-DNA
Extra Polymeric Substances	:	EPS
Extra Polymeric Matrix	:	EPM
Fourier Transform infrared	:	FT-IR
Gram	:	g
Heanotoxylin and Eosin	:	H&E
Hour	:	h
High Performance Liquid Chromatography	:	HPLC
Histone Acetyl Transferase	:	HAT
Hydroxy Propyl-β-Cyclodextrin	:	HP-β-CD
Hydroxy Propyl Methyl Cellulose	:	HPMC
Kilo Dalton	:	KDa
Luria Bertani	:	LB

Scanned with CamScanner

Microgram	:	μg
Micrometer	:	μm
Milligram	:	mg
Minute	:	min
Milliliter	:	ml
Millimole	:	mM
Minimum Inhibitory Concentration	:	MIC
Molecular Weight	:	MW
Millivolt	:	mV
MMP	:	Matrix Metallo P
Nanometer	:	nm
Nanoparticles	:	NPs
Nanosponge	:	NS
Newton	:	N
Poly Dispersity Index	:	PDI
Particle Size	:	PS
Phosphate Buffer Saline	:	PBS
Response Surface Methodology	:	RSM
Reactive Oxygen Species	:	ROS
Correlation Coefficient	:	R^2
Scanning Electron Microscopy	:	SEM
Solid Lipid Nanoparticles	:	SLNs
Sodium Lauryl Sulfate	:	SLS
Standard Deviation	:	SD
Texture Profile Analysis	:	TPA
Transmission Electron Microscopy	:	TEM
Ultra Violet	:	UV
X-Ray Diffraction	:	XRD
Water in Oil	:	W/O
Percentage	:	%

Scanned with CamScanner

Degree Celsius	:	°C
Wavelength Maxima	:	λmax
Weight/Weight	:	w/w
Weight/Volume	:	w/v
Volume/Volume	:	v/v
Zeta Potential	:	ZP

Scanned with CamScanner